Early lung cancer data show a promising treatment effect for a checkpoint blocker plus antibody-drug conjugate (ADC) combo.
Britain’s AstraZeneca (LSE: AZN) has partnered with Japanese drugmaker Daiichi Sankyo (TY0: 4568) to test the approach in the Phase Ib TROPION-Lung04 study.
The companies are studying the impact of the experimental ADC datopotamab deruxtecan (Dato-DXd), in combination with Imfinzi (durvalumab), with or without chemotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze